HongKong:9996

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio™ Transcatheter Aortic Regurgitation Clinical Trial

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced the completion of patient enrollment and implant...

2024-01-29 21:00 1132

inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America

WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)),announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrenti...

2023-12-05 21:00 1280

Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023

SUZHOU, China, Oct. 27, 2023 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at ...

2023-10-27 20:00 1259

Peijia Medical Announces 2023 Interim Results

HONG KONG , Sept. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial results for the six months endedJune 30, 2023 ("the period...

2023-09-01 19:00 4248

Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System

SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced onJuly 31, 2023 that the first Chinese patient of the multi-center ...

2023-08-01 20:00 1567

Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System

SUZHOU, China, Nov. 25, 2022 /PRNewswire/ -- inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrentia...

2022-11-25 16:00 2327

Peijia Medical Announces 2021 Annual Results

Dual Engines Promote Commercialization Total Revenue Increased by 253.2% HONG KONG, April 2,  2022 /PRNewswire/ -- Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996), a leading player in the high-growth transcatheter valve th...

2022-04-02 00:06 9821

Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region

SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...

2022-01-19 20:00 3285

Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology

SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...

2021-12-30 19:18 2195

Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®

SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve ("TAVR") system, following the first successful patient implant in Zhongshan Hospital of Fudan Univers...

2021-09-14 22:11 4380

Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant

SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...

2021-09-06 13:44 3555

With the Second-Generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the "Retrievable Era" using TAVR products

SUZHOU, China, June 28, 2021 /PRNewswire/ -- The TaurusElite® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusElite®") developed by Peijia Medical (9996.HK) is approved for marketing by the National Medical Products Administration (NMPA) inJune 2021 (Reg. No. GXZZ...

2021-06-28 11:15 8070

Peijia Medical's Jasper® SS Detachable Coil Receives NMPA Approval for Commercialization

SUZHOU, China, June 24, 2021 /PRNewswire/ -- On June 15, 2021, Jasper® SS—a new detachable coil independently developed by Achieva Medical, subsidiary of Peijia Medical (9996.HK)—was approved by the National Medical Products Administration ("NMPA") for commercialization (registration number GXZZ ...

2021-06-25 00:27 16086

Peijia Medical Partners with inQB8 for US Incubator and Transcatheter Tricuspid Replacement (TTVR) Product

SUZHOU, China, June 9, 2021 /PRNewswire/ -- Peijia Medical (HKEX:9996, or " Peijia"), a leading player in China for medical technology, announced a partnership withinQB8, a Boston based medical technology incubator, to explore innovative solutions for Structural Heart Disease. This partnership inc...

2021-06-10 10:26 18892

Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization

SUZHOU, China, April 24, 2021 /PRNewswire/ -- A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusOne®") developed by Peijia Medical (Suz...

2021-04-25 08:53 2510

Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product

SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Peijia Medical (HK Stock Code: 09996) successfully commenced the animal experiment for its mitral valve edge-to-edge repair product, advancing the development to the next stage. The commencement of this experiment reflects Peijia Medical's long term com...

2020-12-08 20:00 2963

Week's Top Stories